Emerging drugs for hepatocellular carcinoma

Bibliography

• YEO W, MOK TS, ZEE B et al.: A randomized Phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. (2005) 97(20):1532-1538.
   PubMed Web of Science ®Google Scholar
• LEE JS, THORGEIRSSON SS: Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 127(5 Suppl. 1):S51-S55.
   PubMed Web of Science ®Google Scholar
• THORGEIRSSON SS, LEE JS, GRISHAM JW: Functional genomics of hepatocellular carcinoma. Hepatology (2006) 43(S1):S145-S150.
   PubMed Web of Science ®Google Scholar
• LAURENT-PUIG P, LEGOIX P, BLUTEAU O et al.: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 120(7):1763-1773.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
   PubMed Web of Science ®Google Scholar
• GREEN DR, EVAN GI: A matter of life and death. Cancer Cell (2002) 1(1):19-30.
   PubMed Web of Science ®Google Scholar
• LOWE SW, CEPERO E, EVAN G: Intrinsic tumour suppression. Nature (2004) 432(7015):307-315.
   PubMed Web of Science ®Google Scholar
• SCHMITT CA, FRIDMAN JS, YANG M et al.: Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 1(3):289-298.
   PubMed Web of Science ®Google Scholar
• KITAMURA Y, HIROTAB S: Kit as a human oncogenic tyrosine kinase. Cell. Mol. Life Sci. (2004) 61(23):2924-2931.
   PubMed Web of Science ®Google Scholar
• JONES AV, CROSS NC: Oncogenic derivatives of platelet-derived growth factor receptors. Cell. Mol. Life Sci. (2004) 61(23):2912-2923.
   PubMed Web of Science ®Google Scholar
• RAMADORI G, FUZESI L, GRABBE E, PIELER T, ARMBRUST T: Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anti-Cancer Drugs (2004) 15(4):405-409.
   PubMed Web of Science ®Google Scholar
• ECKEL F, VON DELIUS S, MAYR M et al.: Pharmacokinetic and clinical Phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology (2005) 69(5):363-371.
   PubMed Web of Science ®Google Scholar
• SHACHAF CM, KOPELMAN AM, ARVANITIS C et al.: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 431(7012):1112-1117.
   PubMed Web of Science ®Google Scholar
• SHACHAF CM, FELSHER DW: Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res. (2005) 65(11):4471-4474.
   PubMed Web of Science ®Google Scholar
• AL-HAJJ M, CLARKE MF: Self-renewal and solid tumor stem cells. Oncogene (2004) 23(43):7274-7282.
   PubMed Web of Science ®Google Scholar
• LEE JS, HEO J, LIBBRECHT L et al.: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. (2006) 12(4):410-416.
   PubMed Web of Science ®Google Scholar
• PIKARSKY E, PORAT RM, STEIN I et al.: NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 431(7007):461-466.
   PubMed Web of Science ®Google Scholar
• NAKAMOTO Y, GUIDOTTI LG, KUHLEN CV, FOWLER P, CHISARI FV: Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. (1998) 188(2):341-350.
   PubMed Web of Science ®Google Scholar
• YE QH, QIN LX, FORGUES M et al.: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. (2003) 9(4):416-423.
   PubMed Web of Science ®Google Scholar
• STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. (2005) 23(5):965-972.
   PubMed Web of Science ®Google Scholar
• WEDGE SR, KENDREW J, HENNEQUIN LF et al.: AZD-2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. (2005) 65(10):4389-4400.
   PubMed Web of Science ®Google Scholar
• CARLONI V, VIZZUTTI F, PANTALEO P: Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. Clin. Cancer Res. (2005) 11(11):4266-4274.
   PubMed Web of Science ®Google Scholar
• WALKER K, OLSON MF: Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. (2005) 15(1):62-68.
   PubMed Web of Science ®Google Scholar
• WONG WW, DIMITROULAKOS J, MINDEN MD, PENN LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 16(4):508-519.
   PubMed Web of Science ®Google Scholar
• KAWATA S, YAMASAKI E, NAGASE T et al.: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer (2001) 84(7):886-891.
   PubMed Web of Science ®Google Scholar
• GILES RH, VAN ES JH, CLEVERS H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta (2003) 1653(1):1-24.
   PubMed Web of Science ®Google Scholar
• LEE HC, KIM M, WANDS JR: Wnt/Frizzled signaling in hepatocellular carcinoma. Front. Biosci. (2006) 11:1901-1915.
   PubMed Web of Science ®Google Scholar
• LEPOURCELET M, CHEN YN, FRANCE DS et al.: Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell (2004) 5(1):91-102.
   PubMed Web of Science ®Google Scholar
• EMAMI KH, NGUYEN C, MA H et al.: A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA (2004) 101(34):12682-12687.
   PubMed Web of Science ®Google Scholar
• YOU L, HE B, XU Z et al.: An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. (2004) 64(15):5385-5389.
   PubMed Web of Science ®Google Scholar
• YOU L, HE B, XU Z et al.: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 23(36):6170-6174.
   PubMed Web of Science ®Google Scholar
• BURGER AM, SETH AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer (2004) 40(15):2217-2229.
   PubMed Web of Science ®Google Scholar
• YANG Y, LI CC, WEISSMAN AM: Regulating the p53 system through ubiquitination. Oncogene (2004) 23(11):2096-2106.
   PubMed Web of Science ®Google Scholar
• DONG Y, HAKIMI MA, CHEN X et al.: Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell (2003) 12(5):1087-1099.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, CHANG C, GEHLING DJ, HEMMATI-BRIVANLOU A, DERYNCK R: Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA (2001) 98(3):974-979.
   PubMed Web of Science ®Google Scholar
• WANG F, DENISON S, LAI JP et al.: Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer (2004) 40(2):85-96.
   PubMed Web of Science ®Google Scholar
• ZAVRSKI I, JAKOB C, SCHMID P et al.: Proteasome: an emerging target for cancer therapy. Anti-Cancer Drugs (2005) 16(5):475-481.
   PubMed Web of Science ®Google Scholar
• DY GK, THOMAS JP, WILDING G et al.: A Phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin. Cancer Res. (2005) 11(9):3410-3416.
   PubMed Web of Science ®Google Scholar
• VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303(5659):844-848.
   PubMed Web of Science ®Google Scholar
• GANTEN TM, KOSCHNY R, HAAS TL et al.: Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology (2005) 42(3):588-597.
   PubMed Web of Science ®Google Scholar
• KOURAKLIS G, THEOCHARIS S: Histone deacetylase inhibitors and anticancer therapy. Curr. Med. Chem. Anti-Cancer Agents (2002) 2(4):477-484.
   PubMedGoogle Scholar
• MONNERET C: Histone deacetylase inhibitors. Eur. J. Med. Chem. (2005) 40(1):1-13.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, FUJIMOTO J, OKAMOTO E et al.: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int. J. Cancer (1998) 76(6):897-902.
   PubMed Web of Science ®Google Scholar
• HEROLD C, GANSLMAYER M, OCKER M et al.: The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. (2002) 36(2):233-240.
   PubMed Web of Science ®Google Scholar
• YAMASHITA Y, SHIMADA M, HARIMOTO N et al.: Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer (2003) 103(5):572-576.
   PubMed Web of Science ®Google Scholar
• SCHUCHMANN M, SCHULZE-BERGKAMEN H, FLEISCHER B et al.: Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol. Rep. (2006) 15(1):227-230.
   PubMed Web of Science ®Google Scholar
• CORADINI D, ZORZET S, ROSSIN R et al.: Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. (2004) 10(14):4822-4830.
   PubMed Web of Science ®Google Scholar
• ZHU WG, OTTERSON GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Cancer Agents (2003) 3(3):187-199.
   PubMedGoogle Scholar
• CHAN S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer (2004) 91(8):1420-1424.
   PubMed Web of Science ®Google Scholar
• HORIE Y, SUZUKI A, KATAOKA E et al.: Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. (2004) 113(12):1774-1783.
   PubMed Web of Science ®Google Scholar
• SAHIN F, KANNANGAI R, ADEGBOLA O et al.: mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. (2004) 10(24):8421-8425.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER G, OIDTMANN M, ROSEWICZ S et al.: Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant. Proc. (2002) 34(5):1392-1393.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER G, OIDTMANN M, RUEGGEBERG A et al.: Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J. Gastroenterol. (2005) 11(10):1420-1425.
   PubMed Web of Science ®Google Scholar
• DALGIC A, KARAKAYALI H, MORAY G et al.: Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria. Transplant. Proc. (2005) 37(7):3154-3156.
   PubMed Web of Science ®Google Scholar
• STIPPEL DL, KASPER HU, SCHLEIMER K et al.: Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant. Proc. (2005) 37(5):2185-2187.
   PubMed Web of Science ®Google Scholar
• ELSHARKAWI M, STAIB L, HENNE-BRUNS D, MAYER J: Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation (2005) 79(7):855-857.
   PubMed Web of Science ®Google Scholar
• KNETEMAN NM, OBERHOLZER J, AL SAGHIER M et al.: Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. (2004) 10(10):1301-1311.
   PubMed Web of Science ®Google Scholar
• LANE: Program and Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Hynes Center, Boston, MA, USA (2003):259-260.
   Google Scholar
• MITA MM, ROWINSKI EK, GOLDSTON ML et al.: 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. (2004) 22(14):3076.
   Google Scholar
• YU K, TORAL-BARZA L, DISCAFANI C et al.: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer (2001) 8(3):249-258.
   PubMed Web of Science ®Google Scholar
• TSUBOI S, NOUSO K, TOMONO Y et al.: Anti-endostatin monoclonal antibody enhances growth of human hepatocellular carcinoma cells by inhibiting activity of endostatin secreted by the transplanted cells in nude mice. Int. J. Oncol. (2004) 25(5):1267-1271.
   PubMed Web of Science ®Google Scholar
• LI G, SHAM J, YANG J et al.: Potent antitumor efficacy of an E1B 55 kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int. J. Cancer (2005) 113(4):640-648.
   PubMed Web of Science ®Google Scholar
• GRATTON JP, LIN MI, YU J et al.: Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell (2003) 4(1):31-39.
   PubMed Web of Science ®Google Scholar
• PATT YZ, HASSAN MM, LOZANO RD et al.: Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am. J. Clin. Oncol. (2000) 23(3):319-321.
   PubMed Web of Science ®Google Scholar
• PATT YZ, HASSAN MM, LOZANO RD et al.: Thalidomide in the treatment of patients with hepatocellular carcinoma. Cancer (2005) 103(4):749-755.
   PubMed Web of Science ®Google Scholar
• HAVIV F, BRADLEY MF, KALVIN DM et al.: Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J. Med. Chem. (2005) 48(8):2838-2846.
   PubMed Web of Science ®Google Scholar
• HOEKSTRA R, DE VOS FY, ESKENS FA et al.: Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J. Clin. Oncol. (2005) 23(22):5188-5197.
   PubMed Web of Science ®Google Scholar
• SUDHAKAR A, SUGIMOTO H, YANG C et al.: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc. Natl. Acad. Sci. USA (2003) 100(8):4766-4771.
   PubMed Web of Science ®Google Scholar
• MIURA N, HORIKAWA I, NISHIMOTO A et al.: Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet. (1997) 93(1):56-62.
   PubMed Web of Science ®Google Scholar
• STEWART SA,WEINBERG RA: Telomerase and human tumorigenesis. Semin. Cancer Biol. (2000) 10(6):399-406.
   PubMed Web of Science ®Google Scholar
• KOJIMA H, YOKOSUKA O, IMAZEKI F, SAISHO H,OMATA M: Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology (1997) 112(2):493-500.
   PubMed Web of Science ®Google Scholar
• NAGAO K, TOMIMATSU M, ENDO H, HISATOMI H, HIKIJI K: Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J. Gastroenterol. (1999) 34(1):83-87.
   PubMed Web of Science ®Google Scholar
• NATARAJAN S, CHEN Z, WANCEWICZ EV, MONIA BP, COREY DR: Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. Oligonucleotides (2004) 14(4):263-273.
   PubMed Web of Science ®Google Scholar